ABSTRACT. Milrinone may be used in the treatment of pulmonary hypertensive diseases of the newborn. We have studied its effects in chronically instrumented newborn lambs over a dose range from 1-100 pg/kg. These actions have been compared with those of amrinone. We have also tested the effect of milrinone on hypoxia and leukotriene D4-induced pulmonary vasoconstriction. Injected into the right pulmonary artery, both amrinone and milrinone cause a dose-related fall in pulmonary arteriolar resistance with milrinone being approximately 20 times more potent than amrinone and possessing an ED-of about 10 pg/kg. Both agents increase left ventricular dp/dt significantly and tend to increase cardiac output. Systemic vascular resistance falls with both drugs but the change is significant only with milrinone. While milrinone attenuates the increase in pulmonary arteriolar resistance induced by leukotriene D4 and hypoxia, this is probably an indirect effect. Milrinone does not modify either the increases in left atrial, aortic pressure, and systemic vascular resistance or the decreases in cardiac output and left ventricular dp/dt induced by leukotriene D4. These findings suggest that milrinone deserves clinical trial in newborn infants with pulmonary hypertension in whom myocardial depression often coexists. (Pediatr Res 22: 422-428, 1987) Abbreviations Impaired coronary perfusion and systemic hypoxemia often depress myocardial function in these patients, thereby adding to the therapeutic problem. Indeed, severe forms of this syndrome carry a 25 to 30% mortality (1, 2).
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Because active pulmonary vasoconstriction is believed to be a significant factor in the pathogenesis of persistent pulmonary hypertension, many vasodilators have been tried with inconsistent effects. With most such drugs systemic vasodilation with hypotension limits their usefulness.
The bipyridine derivatives, amrinone [WIN 40680, 5-amino-3, 4'-bipyridine-6(1H)-one] and milrinone [WIN 47203, 1,6-dihydro-2-methyl-6-oxo(3,4'-bipyridine)-5-carbonitrile] are positive inotropic agents in animals (3) and humans (4, 5) and smooth muscle relaxants. Amrinone has been the subject of a limited trial in children with pulmonary hypertension. In neonates it was possibly harmful, while in older children its benefits were limited by the rapid onset of tachyphylaxis (6) . We have therefore studied the pulmonary vascular, cardiac, and systemic effects of milrinone in conscious, chronically instrumented young lambs and its effect on pulmonary vasoconstriction due hypoxia, leukotriene D4, or both. Amrinone was also studied in one group of animals to provide comparative data. Milrinone differs from amrinone in being stable to light, it does not exhibit tachyphylaxis in adults (7) Persistent pulmonary hypertension of the newborn describes a syndrome in which increased pulmonary vascular resistance is associated with right-to-left shunting through the foramen ovale and the ductus arteriosus. It excludes pulmonary hypertension secondary to cardiac malformations.
Possible etiologic factors include perinatal hypoxemia, fetal hypertension, in utero constriction of the ductus arteriosus either spontaneous or secondary to maternal ingestion of nonsteroidal antiinflammatory agents, lithium intoxication, and neonatal polycythemia.
omy was performed and two modified C &. C Instruments electromagnetic flow probes were implanted, one around the right pulmonary artery and the other around the left pulmonary artery. Access to the right pulmonary artery was gained after ligating and dividing the ductus arteriosus. A special cannula through which a 41 cm, 3.5 French umbilical catheter (Argyle) could be passed was chronically implanted in the left atrium and secured by a purse string (8) . The cannula was made from PE tubing (PE 205, OD 2.08 mm and ID 1.57 mm). A second smaller PE cannula (PE 90, OD 1.27 mm and ID 0.8 mm) was used to cannulate the right lower pulmonary vein.
At least 3 days were allowed for recovery from surgery. Any animal with evidence of respiratory distress was not used for subsequent drug studies.
Gentamicin (2 mg/kg) and ampicillin (125 mg) were administered intramuscularly postoperatively and twice daily thereafter.
Experimental procedure. The day before the drug study, a cutdown in the neck was performed under inhalation anaesthesia
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(halothane 0.5%, nitrous oxide 5 liter/min, oxygen 5 literlmin), which allowed the chronic placement of three vascular cannulae (Cook's Desilet-Hoffman Sheath Set) into a carotid artery (8 French) and both external jugular veins (7 French) . Through these cannula, three additional catheters were introduced, one in the right atrium, a second in the right pulmonary artery with its tip just beyond the flow probe, and the third, a 5 French Millar high fidelity catheter, in the left ventricle. A Cook's Check-flo with a side connector was connected to the 8 French arterial cannula through which the high-fidelity catheter was passed. This arrangement allowed simultaneous arterial blood sampling and pressure monitoring through the side connection.
The fluid-filled catheters were connected to Statham P23dB strain gauge transducers, the flow probes to Statham SP2202 flow meters, and the Millar high fidelity catheter to a Millar Transducer Control Unit (model TCB 100). All signals (right and left pulmonary arterial flow, pulmonary, aortic, right and left atrial, pulmonary venous and left ventricular pressures, and left ventricular dp/dt) were displayed and continuously recorded on an Electronics for Medicine DR-8 optical recorder. Zero pressure was taken at midchest position. Three drugs were used in the experiments: amrinone alone (group l), milrinone alone (group 2), leukotriene D4 before and after treatment with milrinone (group 3). On each study day, only one test condition was used. Five animals were used in each group. Dose responses to amrinone ( 100, 200, 500, and 1000 pg/kg) and milrinone (1, 10,50, and 100 pg/kg) were obtained by using bolus injections into the right pulmonary artery. Thirty min were allowed to elapse between injections. The same sequence of dosage from low to high was used in all experiments. Flows and pressures were recorded continuously for the first 10 min after the injection and then at 5-min intervals thereafter. In two animals in group 1 and all animals in group 2, a control hypoxic pulmonary vasoconstrictor response was elicited before the drug test. In all animals in groups 1 and 2, the hypoxic response was again elicited 30 min after the last dose of amrinone or milrinone.
In group 3, bolus injections of leukotriene D4 (1 pg/kg) and milrinone (50 pg/kg) were given into the right pulmonary artery. Ten min were allowed to elapse between the injections, during which the pressures and flows were monitored continuously. The test sequence was as follows: control bolus injections of leukotriene D4 were made in room air and the hemodynamic effects measured. After return to baseline, hypoxia was induced. A second bolus injection of leukotriene D4 was made during sustained hypoxia. The animals were then returned to room air, and milrinone 50 pg/kg was administered after the hemodynamic parameters had returned to baseline normoxic levels. Ten min after this, bolus injections of leukotriene D4 were repeated during room air breathing and during sustained hypoxia.
During the study, the lamb was lightly restrained in a wooden frame. Normocapnic hypoxia was achieved by placing the animal in a plexiglass box through which a mixture of nitrogen, oxygen, and carbon dioxide was circulated to achieve a FiOl of 0.10-0.12. The hypoxic mixture was monitored continuously with a Critikon Oxycheck oxygen meter.
DRUGS AND SOLUTIONS
Amnnone was supplied in 1-ml ampoules containing amnnone as lactate equivalent to 5 mg and 0.25 mg sodium metabisulfite. Great care was taken in preventing its exposure to light. Milrinone powder was dissolved in 0.5 N lactic acid (2 mg/ml) and this stock solution was diluted with saline to the desired concentration.
An aqueous solution of synthetic leukotriene D4 1 mg/ml (courtesy of Dr. J. Rokach, Merck Frosst) was diluted with icecold Tris buffer (1 50 mM, pH 7.4).
Milrinone determination. Two ml of blood were withdrawn from the aorta into oxalated tubes 30 s after injection of milrinone and the plasma was separated and frozen. Plasma levels of milrinone were subsequently measured using the method of Edelson et al. (9) and a Waters 840 HPLC system.
The results are expressed as means * SEM and analyzed by Student's t test (paired or unpaired) or ANOVA. Significance is regarded as a p value of less than 0.05. When a significant F value was obtained, the means were compared using Duncan's multiple range test. The surgical and experimental procedures were approved by the Animal Care Committee of the Research Institute, The Hospital for Sick Children, Toronto.
RESULTS
Group 1.
Amrinone caused a dose-related fall in pulmonary arteriolar resistance in the injected lung (Fig. I) . The hemodynamic effect of the 1000 pg/kg dose are shown in Figure 2 . Left ventricular dp/dt increased significantly ( p < 0.05). Systemic vascular resistance tended to fall in a dose-dependent fashion although the fall did not achieve significance. Intmpulmonary amrinone produced a redistribution of pulmonary blood flow toward the injected lung indicating a direct vasodilator effect. heart rate (HR) -, pulmonary artery pressure (PAP) 0--0, left ventricular (LV) dp/dt, U ; cardiac index (CZ) W; and pulmonary arteriolar resistance (PAR) A-A.
The same abbreviations are used in subsequent figures. The percent change in the ratio of Qinj to total Qt was significant for the highest dose with a shift toward the injected lung (Table  1) .
Group 2. The vehicle (1.5 ml) had no effect on any of the hemodynamic parameters measured. As with amrinone, milrinone caused a dose-related fall in pulmonary arteriolar resistance (Fig. 3) and a dose-related increase in the ratio Qinj/Qt ( Table  1 ). The effects of 50 and 100 pg/kg of milrinone were comparable to that of 1000 pg/kg of amrinone (Figs. 1 and 3) . The ED50 for these actions was about 10 pg/kg.
Pulmonary artery pressure fell while cardiac output increased slightly (Fig. 4) . Milrinone also caused a significant fall in systemic resistance (Fig. 5) .
Bolus injections of 50 pg/kg of milrinone increased the heart rate by 28 beatslmin, and left ventricular dp/dt by 1980 mm Hg/s or 59% ( p < 0.01). This rise in left ventricular dp/dt is more than can be accounted for by the concomitant tachycardia (10) .
Group 3. Leukotriene D4 (1 pg/kg) caused pulmonary arteriolar constriction. This response was significantly attenuated by pretreatment with milrinone 50 pg/kg (Fig. 6 ). Leukotriene D4 also caused significant increases in left atrial pressure, aortic pressure, and systemic vascular resistance while decreasing cardiac output and left ventricular dp/dt (Fig. 7) and the flow ratio Qinj/Qt (Table 1) . None of these changes was modified significantly by milrinone pretreatment.
Hypoxia. Hypoxia was used to induce heightened pulmonary vascular tone. Arterial blood gases were not significantly different between any of the groups before hypoxia and PO2 fell to a similar degree (Table 2 ). Both amrinone and milrinone lowered the increase in pulmonary artery pressure and pulmonary arteriolar resistance induced by hypoxia. Similarly milrinone attenuated the response to leukotriene D4 during both normoxia and hypoxia. The differences between control response and after treatment response were significant in all cases (Table 2) .
Plasma levels. Plasma concentrations of milrinone increased with increasing dosage, and up to the 50 pg/kg dose were inversely related to the fall in pulmonary arteriolar resistance in the injected lung (Fig. 8) . There was no difference between the fall in pulmonary arteriolar and systemic resistances in response to 50 pg/kg.
DISCUSSION
Amrinone and its 2-methyl, 5-carbonitrile derivative milrinone are new agents with positive inotropic actions which are undergoing trials in the treatment of adults with congestive heart failure. They also relax vascular smooth muscle, including human umbilical arteries (1 1) and bovine intrapulmonary arteries (12) . This action is not significantly affected by histamine H, and H2 receptor blockers, cholinergic and adrenergic blockers, prostaglandin synthetase inhibitors, and is independent of muscarinic receptors. Evidence is accumulating that the bipyridines may relax vascular smooth muscle by affecting both calcium influx and its intracellular release. However, their mechanism of action is far from clear.
In isolated rat lungs amrinone dilates the pulmonary vessels and blunts hypoxic vasoconstriction (13). Mammel et al. (14) using a similar experimental model to ours showed that amrinone is a pulmonary vasodilator. Subsequent clinical studies were * Arterial blood gases in room air and during hypoxia before (control) and after pretreatment with either amrinone or milrinone. APAP = increase in pulmonary artery pressure. APAR = increase ip pulmonary qrteriolar resistance in response to hypoxia (groups 1 and 2) and to leukotriene D4 1 rg/kg in group 3. Leukotriene D4 was tested in room air and hypoxia, before and after milrinone 50 pg/kg. All differences between control and treatment values for APAP and APAR are significant ( p < 0.05). Group 1, unpaired data, groups 2 and 3, paired data (n = 5 for all observations except group 1 control PO2 in which there were only two measurements). PO2 and PC02 in mm Hg. disappointing (6) . In four neonates, 12-36 h old, intravenous amrinone lowered systemic pressure and arterial PO2 with an apparent increase in cyanosis. In five older children with pulmonary hypertension, the initial dose of amrinone markedly decreased pulmonary artery pressure but in three of the five subsequent doses had little effect. Furthermore, frequent and potentially serious side-effects have been observed in adults including abdominal pain, nausea and vomiting, liver damage, myositis, pulmonary infiltrates, and polyserositis (15, 17) . Thrombocytopenia without complication has also been reported (1 8).
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Tachyphylaxis has not been reported with milrinone during its use in adults and over the short term it appears to be well tolerated without fever, thrombocytopenia, or gastrointestinal effects (7) . Milrinone has the further advantage of being stable on exposure to light. The pulmonary vascular effects of milrinone have not been reported previously. Our studies show that it has significant relaxant action on pulmonary arterioles in young animals (ED50 -1 0 pg/kg) that is approximately 20 times more potent than amrinone. This action is coupled with the expected positive inotropic action on the heart and systemic vasodilation.
Leukotrienes have been implicated as the mediator of hypoxic pulmonary vasoconstriction (19) and possible in the control of pulmonary blood flow in the fetus (20) . We have previously demonstrated leukotriene D, to be a potent pulmonary vasoconstrictor in both lambs and piglets (2 1,22) with negative inotropic properties (22) . Our results suggest that milrinone blunts both hypoxia and leukotriene-induced pulmonary arteriolar constriction without significant effect on the leukotriene systemic action or on its negative inotropic effect. However, this apparent blunting is not reflected in the effect on the ratio Qinj/Qt which suggests it may be an indirect action. The antagonistic action of milrinone on leukotriene effects is probably nonspecific but may be exerted through the common influence of these compounds on calcium fluxes (23) .
The inotropic properties of amrinone have been demonstrated in isolated tissues (24) and humans (25) . In anesthetized dogs bolus injections of amrinone increased flow to the left ventricle but the ratio of endocardial-to-epicardial perfusion fell, an effect that might encourage subendocardial ischemic damage in pathologic situations (26) . The present study documents a direct positive inotropic action of milrinone in young lambs as judged by an increase in left ventricular dp/dt after its administration, which is greater than can be accounted for by the associated tachycardia (10) . The concomitant fall in systemic resistance seen in our animals would be expected to reduce peak left ventricular dp/dt (27) .
Pulmonary hypertension in the newborn is usually associated with right-to-left shunts through the foramen ovale and ductus arteriosus, factors that are often combined with myocardial depression. The "ideal" drug in these circumstances would be one in which completely selective pulmonary vasodilatation is coupled to a positive inotropic action on the heart. Effects on systemic resistance should be minimal. While milrinone is not ideal, our findings suggest that it is worth a trial in the management of these difficult clinical problems. It is a more potent pulmonary vasodilator than amrinone, it is a positive inotrope and, at high doses the fall in systemic resistance is much less than the fall in pulmonary resistance. There is some evidence that tachyphylaxis and side-effects are less of a problem with milrinone than amrinone, although the dose response relationship in our experiments suggests tachyphylaxis may be occumng. This will require further evaluation in the clinical setting.
